Inovalon has entered into an agreement with Daiichi Sankyo, to understand the potential role of abuse-deterrent formulations of opioid medications for health plan engagement and support the development of outcomes-based contracts that deliver value to patients, providers and payers. Insights will be gathered through Inovalon’s large-scale, real-world MORE2 Registry dataset, advanced analytic capabilities of the Inovalon ONE Platform, and Avalere’s combined breadth of healthcare capabilities and expertise.
Opioid addiction is one of the most common public health problems in the United States with more than two million people suffering from substance use disorders related to prescription opioid pain relievers. According to the National Institute on Drug Abuse (NIDA), abuse and misuse of prescription opioids costs our healthcare system $26 billion annually. While abuse-deterrent technology is not expected to address all aspects of the opioid epidemic, it is one of a variety of approaches to address this complex problem.
“Daiichi Sankyo is committed to responsibly bringing innovative medicines to patients in pain, and we believe abuse-deterrent formulations are an important part of a comprehensive approach to addressing the inappropriate use of opioid medications,” said Ken Keller, president, administrative and commercial, Daiichi Sankyo, Inc. “Our partnership with Inovalon and Avalere will allow us to achieve innovative approaches to engage health plans and fulfill this commitment.”
“We believe strongly in the benefits of data-driven healthcare and the impact that it can bring to improving desired outcomes,” said Keith Dunleavy, M.D., chief executive officer of Inovalon. “We are pleased that our partnership with Daiichi Sankyo, informed by Inovalon’s MORE2 Registry dataset and the advanced analytics capabilities of the Inovalon ONE Platform, provides an opportunity to expand the applications of our capabilities into the important arena of abuse-deterrent formulations of opioids.”